These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 26025442)

  • 1. Identification of markers that functionally define a quiescent multiple myeloma cell sub-population surviving bortezomib treatment.
    Adomako A; Calvo V; Biran N; Osman K; Chari A; Paton JC; Paton AW; Moore K; Schewe DM; Aguirre-Ghiso JA
    BMC Cancer; 2015 May; 15():444. PubMed ID: 26025442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of eIF2alpha dephosphorylation maximizes bortezomib efficiency and eliminates quiescent multiple myeloma cells surviving proteasome inhibitor therapy.
    Schewe DM; Aguirre-Ghiso JA
    Cancer Res; 2009 Feb; 69(4):1545-52. PubMed ID: 19190324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Role of Chaperone-Mediated Autophagy in Bortezomib Resistant Multiple Myeloma.
    Nikesitch N; Rebeiro P; Ho LL; Pothula S; Wang XM; Khong T; Quek H; Spencer A; Lee CS; Roberts TL; Ling SCW
    Cells; 2021 Dec; 10(12):. PubMed ID: 34943972
    [No Abstract]   [Full Text] [Related]  

  • 4. The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78.
    Roué G; Pérez-Galán P; Mozos A; López-Guerra M; Xargay-Torrent S; Rosich L; Saborit-Villarroya I; Normant E; Campo E; Colomer D
    Blood; 2011 Jan; 117(4):1270-9. PubMed ID: 21106982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular chaperone GRP78 enhances aggresome delivery to autophagosomes to promote drug resistance in multiple myeloma.
    Abdel Malek MA; Jagannathan S; Malek E; Sayed DM; Elgammal SA; Abd El-Azeem HG; Thabet NM; Driscoll JJ
    Oncotarget; 2015 Feb; 6(5):3098-110. PubMed ID: 25605012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacologic screens reveal metformin that suppresses GRP78-dependent autophagy to enhance the anti-myeloma effect of bortezomib.
    Jagannathan S; Abdel-Malek MA; Malek E; Vad N; Latif T; Anderson KC; Driscoll JJ
    Leukemia; 2015 Nov; 29(11):2184-91. PubMed ID: 26108695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Upregulation of FOXM1 leads to diminished drug sensitivity in myeloma.
    Gu C; Jing X; Holman C; Sompallae R; Zhan F; Tricot G; Yang Y; Janz S
    BMC Cancer; 2018 Nov; 18(1):1152. PubMed ID: 30463534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolonged early G(1) arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4.
    Huang X; Di Liberto M; Jayabalan D; Liang J; Ely S; Bretz J; Shaffer AL; Louie T; Chen I; Randolph S; Hahn WC; Staudt LM; Niesvizky R; Moore MA; Chen-Kiang S
    Blood; 2012 Aug; 120(5):1095-106. PubMed ID: 22718837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB.
    Buontempo F; Orsini E; Lonetti A; Cappellini A; Chiarini F; Evangelisti C; Evangelisti C; Melchionda F; Pession A; Bertaina A; Locatelli F; Bertacchini J; Neri LM; McCubrey JA; Martelli AM
    Oncotarget; 2016 Jan; 7(2):1323-40. PubMed ID: 26593250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SGK Kinase Activity in Multiple Myeloma Cells Protects against ER Stress Apoptosis via a SEK-Dependent Mechanism.
    Hoang B; Shi Y; Frost PJ; Mysore V; Bardeleben C; Lichtenstein A
    Mol Cancer Res; 2016 Apr; 14(4):397-407. PubMed ID: 26869290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of GRP78, Master Regulator of the Unfolded Protein Response, Increases Chemoresistance in Pancreatic Ductal Adenocarcinoma.
    Gifford JB; Huang W; Zeleniak AE; Hindoyan A; Wu H; Donahue TR; Hill R
    Mol Cancer Ther; 2016 May; 15(5):1043-52. PubMed ID: 26939701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of serum glucose-regulated protein 78 (GRP78) as a biomarker of treatment response to bortezomib-based induction regimen in multiple myeloma: A cross-sectional pilot study.
    Ramachandran SS; Gupta P; Kumar L; Gupta R; Goel L; Kumar VL; Gupta YK
    Neoplasma; 2022 Dec; 69(6):1451-1458. PubMed ID: 36591800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced response of IRE1α/Xbp-1 signaling pathway to bortezomib contributes to drug resistance in multiple myeloma cells.
    Xu X; Liu J; Huang B; Chen M; Yuan S; Li X; Li J
    Tumori; 2017 May; 103(3):261-267. PubMed ID: 27647225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The expression of the endoplasmic reticulum stress sensor BiP/GRP78 predicts response to chemotherapy and determines the efficacy of proteasome inhibitors in diffuse large b-cell lymphoma.
    Mozos A; Roué G; López-Guillermo A; Jares P; Campo E; Colomer D; Martinez A
    Am J Pathol; 2011 Nov; 179(5):2601-10. PubMed ID: 21907693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein kinase CK2 protects multiple myeloma cells from ER stress-induced apoptosis and from the cytotoxic effect of HSP90 inhibition through regulation of the unfolded protein response.
    Manni S; Brancalion A; Tubi LQ; Colpo A; Pavan L; Cabrelle A; Ave E; Zaffino F; Di Maira G; Ruzzene M; Adami F; Zambello R; Pitari MR; Tassone P; Pinna LA; Gurrieri C; Semenzato G; Piazza F
    Clin Cancer Res; 2012 Apr; 18(7):1888-900. PubMed ID: 22351691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GRP78 modulates cell adhesion markers in prostate Cancer and multiple myeloma cell lines.
    Cultrara CN; Kozuch SD; Ramasundaram P; Heller CJ; Shah S; Beck AE; Sabatino D; Zilberberg J
    BMC Cancer; 2018 Dec; 18(1):1263. PubMed ID: 30563499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucose-regulated protein 78 (GRP78) as a potential novel biomarker and therapeutic target in multiple myeloma.
    Ninkovic S; Harrison SJ; Quach H
    Expert Rev Hematol; 2020 Nov; 13(11):1201-1210. PubMed ID: 32990063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Covalent CDK7 Inhibitor THZ1 Potently Induces Apoptosis in Multiple Myeloma Cells
    Zhang Y; Zhou L; Bandyopadhyay D; Sharma K; Allen AJ; Kmieciak M; Grant S
    Clin Cancer Res; 2019 Oct; 25(20):6195-6205. PubMed ID: 31358538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MTDH is an oncogene in multiple myeloma, which is suppressed by Bortezomib treatment.
    Gu C; Feng L; Peng H; Yang H; Feng Z; Yang Y
    Oncotarget; 2016 Jan; 7(4):4559-69. PubMed ID: 26683226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NEDD8 Inhibition Overcomes CKS1B-Induced Drug Resistance by Upregulation of p21 in Multiple Myeloma.
    Huang J; Zhou Y; Thomas GS; Gu Z; Yang Y; Xu H; Tricot G; Zhan F
    Clin Cancer Res; 2015 Dec; 21(24):5532-42. PubMed ID: 26156395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.